Authors: Harjunpaa, A Wiklund, T Collan, J Janes, R Rosenberg, J Lee, D Grillo-Lopez, A Meri, S

Citation: A. Harjunpaa et al., Complement activation in circulation and central nervous system after Rituximab (Anti-CD20) treatment of B-Cell lymphoma, LEUK LYMPH, 42(4), 2001, pp. 731-738

Authors: Vose, JM Link, BK Grossbard, ML Czuczman, M Grillo-Lopez, A Gilman, P Lowe, A Kunkel, LA Fisher, RI

Citation: Jm. Vose et al., Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma, J CL ONCOL, 19(2), 2001, pp. 389-397

Authors: Kunkel, L Wong, A Maneatis, T Nickas, J Brown, T Grillo-Lopez, A Benyunes, M Grobman, B Dillman, RO

Citation: L. Kunkel et al., Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: A benefit-risk update, SEMIN ONCOL, 27(6), 2000, pp. 53-61

Authors: Cheson, BD Horning, SJ Coiffier, B Shipp, MA Fisher, RI Connors, JM Lister, TA Vose, J Grillo-Lopez, A Hagenbeek, A Cabanillas, F Klippensten, D Hiddemann, W Castellino, R Harris, NL Armitage, JO Carter, W Hoppe, R Canellos, GP

Citation: Bd. Cheson et al., Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas, J CL ONCOL, 17(4), 1999, pp. 1244-1253